AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) comprising world-leading experts in neurodegenerative diseases, neurosurgical drug delivery and gene therapy development. The newly formed SAB will provide expert guidance to AviadoBio on its current and future research and development strategy, which involves the progression of its lead program in frontotemporal dementia (FTD) into...